Table 1.
Patient demographics and clinical characteristics
| Clinical/Epidemiological Factor | Patients, n (%) (Total N = 542) |
|---|---|
| Median length of follow-up (years) | 2.22 (0.22–6.26) |
| Female sex | 469 (86.5) |
| Race/ethnicity | |
| Asian | 47 (8.7) |
| Black or African American | 124 (22.9) |
| Hispanic or Latino | 60 (11.1) |
| White | 311 (57.4) |
| Anti–AQP4-IgG + | 455 (83.9) |
| Age at disease onset | |
| < 30 years | 151 (27.9) |
| 30–49 years | 260 (48) |
| ≥ 50 years | 131 (24.2) |
| Disease duration before study entrance | |
| < 1 year | 98 (18.1) |
| 1–5 years | 186 (34.3) |
| > 5 years | 258 (47.6) |
| Pre-study ARR (self-reported) | |
| Rate < 0.25 | 249 (45.9) |
| Rate 0.25–0.75 | 166 (30.6) |
| Rate > 0.75 | 127 (23.4) |
| Disease onset phenotype | |
| ON only and ON + BR | 177 (32.7) |
| TM only and TM + BR | 193 (35.6) |
| ON + TM and ON + TM + BR | 58 (10.7) |
| BR only | 35 (6.4) |
| Confirmed through symptoms | 79 (14.6) |
| Comorbidities | |
| Any other autoimmune comorbidity | 153 (28.2) |
| Lupus | 37 (6.8) |
| Sjögren syndrome | 34 (6.3) |
| Rheumatoid arthritis | 15 (2.8) |
| Myasthenia gravis | 11 (2.0) |
| Treatment at study starta | |
| Rituximab | 230 (42.4) |
| Mycophenolate mofetil | 92 (17.0) |
| Maintenance steroids | 67 (12.4) |
| Azathioprine | 64 (11.8) |
| Tocilizumab | 4 (0.7) |
Anti–AQP4-IgG, aquaporin 4 autoantibody; ARR, annualized relapse rate; BR, brain involvement; ON, optic neuritis; TM, transverse myelitis
aTreatment categories are not mutually exclusive. Each is a binary yes/no variable (“yes” level is summarized in this table). It is possible that patients were not on any treatment, multiple treatments, or other treatments on Day 1